Expression and significance of SOX2 in non-small cell lung carcinoma
- Authors:
- Published online on: August 30, 2016 https://doi.org/10.3892/ol.2016.5065
- Pages: 3195-3198
-
Copyright: © Ying et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The aim of the present study was to examine the expression and clinical significance of SOX2 in non-small cell lung carcinoma (NSCLC). Immunohistochemistry was used to detect the expression level of SOX2 in 127 cases of NSCLC. The Chi‑square test was used to analyze the association of SOX2 expression and clinicopathological factors in NSCLC and para‑carcinoma tissues (2.5%). The Kaplan‑Meier method was applied to plot the survival curve, and the log‑rank test and COX multiple regression model were applied to determine survival. SOX2 showed a high expression in 35.4% NSCLC tissues, which was significantly higher than that of the para‑carcinoma tissues. The expression level of SOX2 was not associated with gender, age, smoking history or TNM stage (P>0.05), but was significantly associated with the pathological type of carcinoma. The high expression rate of SOX2 in lung squamous cell carcinoma was 50% (25/50) and in lung adenocarcinoma was 20.3% (12/59). Survival analysis indicated that the prognosis of patients with a high SOX2 expression was significantly better than those with a low SOX2 expression. The COX multiple regression analysis revealed that the expression level of SOX2 was an independent prognostic factor of patients with NSCLC (P<0.001). In conclusion, the expression of SOX2 in NSCLC tissues was upregulated, which was associated with the pathological type of carcinoma, while a high SOX2 expression mainly occurred in lung squamous cell carcinoma.
